<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066923</url>
  </required_header>
  <id_info>
    <org_study_id>EMW-2008-FP-01638</org_study_id>
    <nct_id>NCT01066923</nct_id>
  </id_info>
  <brief_title>Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation</brief_title>
  <acronym>EFFoRT</acronym>
  <official_title>Enhanced Firefighter Rehab Trial: Aspirin Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dave Hostler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal Emergency Management Administration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eyemarker Systems, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if aspirin taken by firefighters prevents platelets
      from becoming sticky when body temperature rises during work in protective clothing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Firefighters have the highest rate of line-of duty death (LODD) in the United States. More
      than half of these LODD are cardiovascular related occurring disproportionately around fire
      suppression activities. In addition, shift work, lifestyle factors, and the exposures
      associated with fire suppression (e.g. smoke, chemicals) may predispose the firefighter to
      earlier onset of heart disease or cause a pro-inflammatory state leading to endothelial
      dysfunction.

      Fire suppression activities exacerbate cardiovascular strain and endothelial dysfunction and
      provide potential triggers for ischemic events (e.g. myocardial infarction, stroke). There is
      a rapid rise in heart rate following the activation of a fire company which may persist for
      as long as 20 minutes. Even in cases where heavy work is not being performed, the repetitive
      upper body exercise associated with tool use raises heart rate disproportionately to oxygen
      consumption.

      Finally, there is a rapid rise in core body temperature from increased physical activity,
      environmental heat and impaired thermoregulation that has been shown to cause
      vasoconstriction and activate coagulation during heat stress (12, 13). This has recently been
      demonstrated in firefighters working in thermal protective clothing. The combination of
      triggers created during fire suppression may result in heart attack or stroke, especially in
      firefighters with risk factors for cardiovascular disease.

      Interventions beyond basic fireground rehab may be required to minimize the effect of these
      triggers and enhance a firefighter's health and wellness. Fireground rehab typically focuses
      on cooling and rehydration of the firefighter following fire suppression or training with the
      assumption that these interventions will correct the underlying pathophysiology. Effective
      fireground rehab must deliver appropriate interventions and monitor the progress of the
      firefighter. While correcting hyperthermia and hypohydration are essential for continued
      performance, it is not clear if these therapies correct alterations in platelet or
      endothelial function or if other interventions are necessary to correct these physiological
      disturbances. Furthermore, the options for monitoring the firefighter beyond simply measuring
      heart and respiratory rate are limited. In our FEMA-funded Fireground Rehab Evaluation (FIRE)
      Trial, we demonstrated that five commercially available thermometers did not reliably measure
      or estimate core temperature following uncompensable heat stress (UHS) making it impossible
      to gauge the effectiveness of rehab interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Closure Time</measure>
    <time_frame>0, 30, 60, and 90 minutes post exercise</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Function Measured by Peripheral Arterial Tonometry</measure>
    <time_frame>Baseline, 30, 60, and 90 minutes post exercise</time_frame>
    <description>Reactive Hyperemia Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of Coagulation</measure>
    <time_frame>0, 30, 60, and 90 minutes post exercise</time_frame>
    <description>This measure was not collected. Equipment was not available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperthermia and Hemoconcentration Identified by Retinal Imaging</measure>
    <time_frame>0, 30, 60, and 90 minutes post exercise</time_frame>
    <description>This measure was not collected. Equipment was not available.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Heat Stress Disorders</condition>
  <arm_group>
    <arm_group_label>Daily ASA, Active cool, Acute ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily ASA, Active cool, Acute placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily ASA, Passive cool, Acute ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily ASA, Passive cool, Acute placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo, active cool, Acute ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo, active cool, Acute placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo, Passive cool, Acute ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily placebo, Passive cool, Acute placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily aspirin (ASA)</intervention_name>
    <description>Two weeks 82 mg aspirin taken orally prior to exercise protocol</description>
    <arm_group_label>Daily ASA, Active cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily ASA, Active cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily ASA, Passive cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily ASA, Passive cool, Acute placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Active cooling</intervention_name>
    <description>Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water</description>
    <arm_group_label>Daily ASA, Active cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily ASA, Active cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily placebo, active cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily placebo, active cool, Acute placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acute aspirin (ASA)</intervention_name>
    <description>325 mg chewable aspirin administered immediately following exercise</description>
    <arm_group_label>Daily ASA, Active cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily ASA, Passive cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily placebo, active cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily placebo, Passive cool, Acute ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Passive cooling</intervention_name>
    <description>Removing protective garments for passive cooling following exercise</description>
    <arm_group_label>Daily ASA, Passive cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily ASA, Passive cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily placebo, Passive cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily placebo, Passive cool, Acute placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daily placebo</intervention_name>
    <description>Placebo comparator for daily aspirin therapy</description>
    <arm_group_label>Daily placebo, active cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily placebo, active cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily placebo, Passive cool, Acute ASA</arm_group_label>
    <arm_group_label>Daily placebo, Passive cool, Acute placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acute placebo</intervention_name>
    <description>Placebo comparator for acute aspirin therapy</description>
    <arm_group_label>Daily ASA, Active cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily ASA, Passive cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily placebo, active cool, Acute placebo</arm_group_label>
    <arm_group_label>Daily placebo, Passive cool, Acute placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Apparently healthy males and females aged 18-49 years

        Exclusion Criteria:

          1. History of heart disease, vascular disease, or sudden death including prior MI,
             coronary revascularization, congenital heart disease or history of stroke

          2. Hypertension during screening: SBP&gt;139 or DBP&gt;89

          3. Those who are taking medications that may be expected to blunt the physiologic
             response to a treadmill exercise test (e.g. beta blockers)

          4. Prescription medication with known side effect of impaired thermoregulation

          5. Positive pregnancy test at any time during the study

          6. Resting ECG with clinical presentation suggesting coronary heart disease (e.g.
             pathologic Q wave)

          7. Known history of gastrointestinal disease or disorder i.e. diverticulitis which
             creates a theoretical risk of the core temperature capsule becoming lodged in the
             digestive tract

          8. Medications and supplements known to alter endothelial function (e.g. arginine, omega
             3 fatty acids, NSAIDS, tobacco products. This exclusion may be disregarded for
             subjects willing to stop taking the supplement for the duration of the study

          9. At the discretion of the study physician for any other medical condition or
             prescription medication

         10. Known history of platelet dysfunction

         11. Aspirin allergy or intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hostler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh, Emergency Responder Human Performance Lab</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.erhpl.org</url>
    <description>Emergency Responder Human Performance Lab</description>
  </link>
  <results_reference>
    <citation>Olafiranye O, Hostler D, Winger DG, Wang L, Reis SE. Effect of aspirin on acute changes in peripheral arterial stiffness and endothelial function following exertional heat stress in firefighters: The factorial group results of the Enhanced Firefighter Rehab Trial. Vasc Med. 2015 Jun;20(3):230-6. doi: 10.1177/1358863X15571447. Epub 2015 May 4.</citation>
    <PMID>25939657</PMID>
  </results_reference>
  <results_reference>
    <citation>Hostler D, Suyama J, Guyette FX, Moore CG, Pryor RR, Khorana P, McEntire SJ, Comer D, Reis SE. A randomized controlled trial of aspirin and exertional heat stress activation of platelets in firefighters during exertion in thermal protective clothing. Prehosp Emerg Care. 2014 Jul-Sep;18(3):359-67. doi: 10.3109/10903127.2013.869644. Epub 2014 Feb 18.</citation>
    <PMID>24548114</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <results_first_submitted>March 18, 2016</results_first_submitted>
  <results_first_submitted_qc>July 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2016</results_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Dave Hostler</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>firefighter</keyword>
  <keyword>heat stress</keyword>
  <keyword>platelet activation</keyword>
  <keyword>aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heat Stress Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/25939657</doc_url>
      <doc_comment>Report of vascular function testing</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/24548114</doc_url>
      <doc_comment>Report of platelet function and physiology</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Active Cooling Arm not completed - insufficient number of subjects were recruited to complete these arms of the trial, and the Passive Cooling arms were the only ones conducted.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Daily ASA, Passive Cool, Acute ASA</title>
          <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
        </group>
        <group group_id="P2">
          <title>Daily ASA, Passive Cool, Acute Placebo</title>
          <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
        </group>
        <group group_id="P3">
          <title>Daily Placebo, Passive Cool, Acute ASA</title>
          <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
        </group>
        <group group_id="P4">
          <title>Daily Placebo, Passive Cool, Acute Placebo</title>
          <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Platelet Closure Time</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vascular Function</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Activation of Coagulation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Retinal Imaging</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daily ASA, Passive Cool, Acute ASA</title>
          <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
        </group>
        <group group_id="B2">
          <title>Daily ASA, Passive Cool, Acute Placebo</title>
          <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
        </group>
        <group group_id="B3">
          <title>Daily Placebo, Passive Cool, Acute ASA</title>
          <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
        </group>
        <group group_id="B4">
          <title>Daily Placebo, Passive Cool, Acute Placebo</title>
          <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="10.1"/>
                    <measurement group_id="B2" value="29.3" spread="8.6"/>
                    <measurement group_id="B3" value="30.5" spread="8.5"/>
                    <measurement group_id="B4" value="34.5" spread="9.3"/>
                    <measurement group_id="B5" value="31.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Closure Time</title>
        <time_frame>0, 30, 60, and 90 minutes post exercise</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daily ASA, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
          </group>
          <group group_id="O2">
            <title>Daily ASA, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
          <group group_id="O3">
            <title>Daily Placebo, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
          </group>
          <group group_id="O4">
            <title>Daily Placebo, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Closure Time</title>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediate post exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275.5" lower_limit="62" upper_limit="300"/>
                    <measurement group_id="O2" value="207" lower_limit="55" upper_limit="300"/>
                    <measurement group_id="O3" value="95" lower_limit="71" upper_limit="182"/>
                    <measurement group_id="O4" value="90" lower_limit="58" upper_limit="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="300" upper_limit="300"/>
                    <measurement group_id="O2" value="300" lower_limit="150" upper_limit="300"/>
                    <measurement group_id="O3" value="300" lower_limit="110" upper_limit="300"/>
                    <measurement group_id="O4" value="105" lower_limit="80" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="300" upper_limit="300"/>
                    <measurement group_id="O2" value="300" lower_limit="120" upper_limit="300"/>
                    <measurement group_id="O3" value="300" lower_limit="125" upper_limit="300"/>
                    <measurement group_id="O4" value="105" lower_limit="80" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="300" upper_limit="300"/>
                    <measurement group_id="O2" value="275" lower_limit="120" upper_limit="300"/>
                    <measurement group_id="O3" value="300" lower_limit="150" upper_limit="300"/>
                    <measurement group_id="O4" value="105" lower_limit="80" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vascular Function Measured by Peripheral Arterial Tonometry</title>
        <description>Reactive Hyperemia Index</description>
        <time_frame>Baseline, 30, 60, and 90 minutes post exercise</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Daily ASA, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
          </group>
          <group group_id="O2">
            <title>Daily ASA, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
          <group group_id="O3">
            <title>Daily Placebo, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
          </group>
          <group group_id="O4">
            <title>Daily Placebo, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Function Measured by Peripheral Arterial Tonometry</title>
          <description>Reactive Hyperemia Index</description>
          <units>ratio (Reactive Hyperemia Index)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.38"/>
                    <measurement group_id="O2" value="1.77" spread="0.51"/>
                    <measurement group_id="O3" value="2.16" spread="0.74"/>
                    <measurement group_id="O4" value="1.72" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.56"/>
                    <measurement group_id="O2" value="1.77" spread="0.38"/>
                    <measurement group_id="O3" value="1.77" spread="0.71"/>
                    <measurement group_id="O4" value="1.73" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="0.48"/>
                    <measurement group_id="O2" value="1.92" spread="0.48"/>
                    <measurement group_id="O3" value="1.56" spread="0.68"/>
                    <measurement group_id="O4" value="1.83" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90 minutes post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.31"/>
                    <measurement group_id="O2" value="1.98" spread="0.45"/>
                    <measurement group_id="O3" value="1.91" spread="0.66"/>
                    <measurement group_id="O4" value="1.98" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activation of Coagulation</title>
        <description>This measure was not collected. Equipment was not available.</description>
        <time_frame>0, 30, 60, and 90 minutes post exercise</time_frame>
        <population>This measure was not collected. Equipment was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily ASA, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
          </group>
          <group group_id="O2">
            <title>Daily ASA, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
          <group group_id="O3">
            <title>Daily Placebo, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
          </group>
          <group group_id="O4">
            <title>Daily Placebo, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Activation of Coagulation</title>
          <description>This measure was not collected. Equipment was not available.</description>
          <population>This measure was not collected. Equipment was not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperthermia and Hemoconcentration Identified by Retinal Imaging</title>
        <description>This measure was not collected. Equipment was not available.</description>
        <time_frame>0, 30, 60, and 90 minutes post exercise</time_frame>
        <population>This measure was not collected. Equipment was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily ASA, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
          </group>
          <group group_id="O2">
            <title>Daily ASA, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
          <group group_id="O3">
            <title>Daily Placebo, Passive Cool, Acute ASA</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
          </group>
          <group group_id="O4">
            <title>Daily Placebo, Passive Cool, Acute Placebo</title>
            <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperthermia and Hemoconcentration Identified by Retinal Imaging</title>
          <description>This measure was not collected. Equipment was not available.</description>
          <population>This measure was not collected. Equipment was not available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Daily ASA, Passive Cool, Acute ASA</title>
          <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise</description>
        </group>
        <group group_id="E2">
          <title>Daily ASA, Passive Cool, Acute Placebo</title>
          <description>Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
Daily aspirin (ASA): Two weeks 82 mg aspirin taken orally prior to exercise protocol
Passive cooling: Removing protective garments for passive cooling following exercise
Acute placebo: Placebo comparator for acute aspirin therapy</description>
        </group>
        <group group_id="E3">
          <title>Daily Placebo, Passive Cool, Acute ASA</title>
          <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
Acute aspirin (ASA): 325 mg chewable aspirin administered immediately following exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy</description>
        </group>
        <group group_id="E4">
          <title>Daily Placebo, Passive Cool, Acute Placebo</title>
          <description>Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
Passive cooling: Removing protective garments for passive cooling following exercise
Daily placebo: Placebo comparator for daily aspirin therapy
Acute placebo: Placebo comparator for acute aspirin therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Detailed results at Olafiranye et al. (2015) Vascular Medicine 20:230-236 and at Hostler et al. (2014) Prehospital Emergency Care 18: 359-367 These papers are linked in the Reference Section</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clifton Callaway</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-647-3078</phone>
      <email>callawaycw@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

